Recent blog posts
Design of Biased Agonists Targeting the Apelin Receptor
Hot Spotlight
6 min read
Design of Biased Agonists Targeting the Apelin Receptor
15 April 2024
The study reveals a structure-guided strategy for biased drug optimization and has led to the development of two biased agonist drug candidates targeting the APLNR receptor.
Read →
Nature: Design of a Novel Bivalent Analgesic Targeting the μ-Opioid Receptor
Hot Spotlight
6 min read
Nature: Design of a Novel Bivalent Analgesic Targeting the μ-Opioid Receptor
10 April 2024
Opioid receptors are crucial for pain relief, blocking pain signal transmission to reduce acute and chronic pain like post-surgery and cancer pain.
Read →
Genfleet Therapeutics Announces the Potential Molecular Structure of Its Oral KRAS G12D Inhibitor through the Publication of its Patent
Hot Spotlight
5 min read
Genfleet Therapeutics Announces the Potential Molecular Structure of Its Oral KRAS G12D Inhibitor through the Publication of its Patent
9 April 2024
On March 28th, Genfleet Therapeutics publicly announced a patent for an oral KRAS G12D inhibitor, with the patent number WO2024061370A1.
Read →
Bivalent Ligands for GPCRs
Hot Spotlight
3 min read
Bivalent Ligands for GPCRs
9 April 2024
Bitopic ligands of GPCRs (G protein-coupled receptors) refer to a single chemical entity composed of two pharmacophoric groups covalently linked together.
Read →
Cell: Designing dual-acting drugs targeting GPCRs using a cheminformatics approach based on variable scaffolds
Hot Spotlight
8 min read
Cell: Designing dual-acting drugs targeting GPCRs using a cheminformatics approach based on variable scaffolds
9 April 2024
On March 28th, the journal "Cell" published an online research paper titled "Flexible Scaffold-based Cheminformatics Approach for Polypharmacological Drug Design".
Read →
The small-molecule CXCR4 antagonist Mavorixafor is used for the treatment of WHIM syndrome and chronic neutropenia
Hot Spotlight
4 min read
The small-molecule CXCR4 antagonist Mavorixafor is used for the treatment of WHIM syndrome and chronic neutropenia
9 April 2024
X4 Pharmaceuticals announced preliminary results from its Phase 2 trial evaluating the safety and efficacy of once-daily oral mavorixafor with or without injected G-CSF in patients with idiopathic, cyclic, or congenital neutropenia.
Read →
Pharvaris is developing a bradykinin B2 receptor antagonist for the treatment of hereditary angioedema
Hot Spotlight
4 min read
Pharvaris is developing a bradykinin B2 receptor antagonist for the treatment of hereditary angioedema
9 April 2024
Deucrictibant is a new, potent oral small-molecule bradykinin B2 receptor antagonist, originally developed by the Pharvaris team.
Read →
AstraZeneca's Novel GR/β2AR Targeted Therapy for Asthma
Hot Spotlight
5 min read
AstraZeneca's Novel GR/β2AR Targeted Therapy for Asthma
3 April 2024
AstraZeneca's Novel GR/β2AR Targeted Therapy for Asthma: Airsupra Approval and Its Implications for Treatment.
Read →
Progress in the Development of Drugs Targeting the PTH1R
Hot Spotlight
5 min read
Progress in the Development of Drugs Targeting the PTH1R
3 April 2024
TransCon PTH, developed by Ascendis Pharma, is an investigational prodrug of PTH hormone undergoing research and development.
Read →
Idiopathic Pulmonary Fibrosis: Current Clinical Research Status Targeting GPCR
Hot Spotlight
7 min read
Idiopathic Pulmonary Fibrosis: Current Clinical Research Status Targeting GPCR
3 April 2024
Idiopathic Pulmonary Fibrosis (IPF) is a progressive lung condition causing scarring and stiffness, which makes breathing harder over time.
Read →
Relaxin Receptors: Therapeutic Opportunity for Heart Failure and Pulmonary Arterial Hypertension
Hot Spotlight
5 min read
Relaxin Receptors: Therapeutic Opportunity for Heart Failure and Pulmonary Arterial Hypertension
2 April 2024
Advancing GPCR-Targeted Therapy: Tectonic Therapeutics' GEODe Platform Overcomes Discovery Challenges.
Read →
New Opportunities in the Development of Therapeutic Drugs for Arteriosclerosis Treatment
Hot Spotlight
8 min read
New Opportunities in the Development of Therapeutic Drugs for Arteriosclerosis Treatment
1 April 2024
Gut-Derived Hormone Cholesin Found to Regulate Cholesterol Metabolism.
Read →